Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration

Pharmacology, Toxicology and Pharmaceutical Science

• Relapse 100%
• Multiple Sclerosis 50%
• Fingolimod 50%
• Rituximab 33%
• Alemtuzumab 33%
• Cladribine 33%
• Ocrelizumab 33%
• Incidence 16%

Immunology and Microbiology

• Fingolimod 50%
• Cells 50%
• Multiple Sclerosis 33%
• Rituximab 33%
• Alemtuzumab 33%
• Ocrelizumab 33%
• Age 16%
• Incidence 16%
• Length 16%

Neuroscience

• Fingolimod 50%
• Multiple Sclerosis 33%
• Rituximab 33%
• Alemtuzumab 33%
• Ocrelizumab 33%
• Cladribine 33%
• Lymphoid Organ 16%